A multivariate analysis was conducted to evaluate the relationship between selected comorbidities and their associated medications, specifically hypertension (ACEi and ARBs), diabetes (biguanides and DPP4 inhibitors), and metabolic disorders (statins). Here, DPP4 is linked to metabolic disease.